The use of cannabinoids in multiple sclerosis.
Naturally occurring cannabinoids including Delta9-tetrahydrocannabinol and cannabidiol as well as endocannabinoids and synthetic cannabinoids may have a role in modulating experimental models of multiple sclerosis. Recent clinical studies to treat symptoms of multiple sclerosis have shown varying results, which may reflect issues relating to the way in which such studies were conducted. There is now increasing interest in the potential role of cannabinoids not only in symptom relief, but also for their possible neuroprotective actions.
Teare
Lara
L
Neurology Research Group, Peninsula Medical School, Plymouth PL6 8BX, UK.
Zajicek
John
J
D000818:Animals; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism / Q000627:therapeutic use*; D002186:Cannabinoids / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000378:metabolism / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy / Q000378:metabolism; D043882:Receptors, Cannabinoid / Q000378:metabolism
D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D018696:Neuroprotective Agents; D043882:Receptors, Cannabinoid